Overview

Vidaza to Restore Hormone Thx Prostate

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a bone marrow disease. The pharmaceutical company involved in this study, Pharmion Corporation, is the manufacturer of Vidaza.
Phase:
Phase 2
Details
Lead Sponsor:
US Oncology Research
Collaborators:
Celgene Corporation
University of Southern California
Treatments:
Azacitidine